Company Monitoring Page for Takeda

latest headlines for company on cafepharma

Puma pounces on failed Takeda drug, snapping up cancer prospect for knockdown price
Fierce Biotech
Wed, 09/21/22 - 10:17 am
Tags:
Puma Biotechnology, Takeda, Aurora A/angiogenic kinase inhibitor, clinical trials, Alisertib
Takeda’s manufacturing site in Belgium gets a €300M boost for plasma therapy production
Endpoints
Wed, 09/14/22 - 07:54 pm
Tags:
Takeda, R&D, drug manufacturing, Belgium, Plasma Therapeutics
One week after Takeda walked away, Finch faces second round of layoffs, pipeline pruning
Endpoints
Thu, 09/1/22 - 10:45 am
Tags:
Finch Therapeutics, Takeda, layoffs, C. difficile
Finch Therapeutics Regains Rights to Two Takeda-Owned IBD Drugs
BioSpace
Fri, 08/26/22 - 10:41 am
Tags:
Takeda, Finch Therapeutics, FIN-524, FIN-525, inflammatory bowel disease
Revealed: which pharma companies leading the way in artificial intelligence
Clinical Trials Arena
Fri, 08/26/22 - 10:37 am
Tags:
artificial intelligence, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Takeda, GSK, Bayer, Astellas
Years after Sanofi's Dengvaxia fiasco, Takeda lands first OK for its own dengue vaccine
Endpoints
Tue, 08/23/22 - 10:27 am
Tags:
Takeda, dengue, vaccines, WHO, TAK-003, Qdenga, Indonesia
Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda
Endpoints
Mon, 08/22/22 - 10:04 am
Tags:
Tessa Therapeutics, Takeda, Thomas Willemsen, CAR-T, Pharma CEOs
Takeda cuts ties to cancer drug landed in $120M Turnstone deal
Fierce Biotech
Thu, 07/28/22 - 10:59 am
Tags:
Takeda, narcolepsy, TAK-994, TAK-605, Turnstone Biologics
A year after netting Takeda partnership, small molecule startup arms itself with some new cash
Endpoints
Wed, 07/27/22 - 10:52 am
Tags:
startups, BridGene Biosciences, Takeda, funding, Eli Lilly
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
BioSpace
Tue, 06/28/22 - 10:49 am
Tags:
EASL, liver disease, Ascletis, Takeda, Arrowhead Pharmaceuticals
Takeda to further cement presence in Cambridge, MA biopharma hub with 600,000-square-foot R&D center
Endpoints
Wed, 06/22/22 - 10:30 am
Tags:
Takeda, biotech hubs, Cambridge MA, R&D
Takeda’s Dengue Fever Vaccine Holds Up Over 4.5 Years
BioSpace
Thu, 06/9/22 - 10:38 am
Tags:
Takeda, TAK-003, vaccines, dengue, clinical trials
Two Remarkable Women of Takeda's C-Suite Make the Professional Personal
BioSpace
Thu, 06/9/22 - 10:17 am
Tags:
Takeda, women executives, Ramona Sequeira, Julie Kim
A ‘perfect storm’ of world calamities may bring down drug prices, Takeda CEO says
Fierce Pharma
Thu, 06/2/22 - 10:28 am
Tags:
Takeda, Pharma CEOs, Christophe Weber, drug prices, climate change, COVID-19, Ukraine
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
BioSpace
Tue, 05/31/22 - 10:32 am
Tags:
Moderna Therapeutics, Takeda, Japan, vaccines, COVID-19
ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug
Fierce Pharma
Fri, 05/27/22 - 10:31 am
Tags:
ASCO 2022, Seagen, Takeda, Adcetris, lymphoma
Ex-Takeda exec hits the ground running at the helm of rare disease biotech — with 3 priorities off the bat
Endpoints
Fri, 05/20/22 - 10:34 am
Tags:
Takeda, Tauhid Ali, rare disease, Oak Hill Bio
Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another
BioSpace
Thu, 05/12/22 - 10:21 am
Tags:
Takeda, earnings, TAK-609, Hunter Syndrome
Takeda, bracing for Vyvanse patent loss, makes strides on debt goal and pivots its focus to launches
Fierce Pharma
Wed, 05/11/22 - 10:49 am
Tags:
Takeda, debt, Vyvanse, patents, earnings
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures
Fierce Biotech
Wed, 05/4/22 - 10:20 am
Tags:
Takeda, gene therapy, rare disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.